Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.

Sheraz Mian headshot

Q4 Earnings Scorecard and Analyst Reports for Microsoft, Thermo Fisher & Union Pacific

by Sheraz Mian

Today's Research Daily features Q4 scorecard and new research reports on Microsoft (MSFT), Thermo Fisher (TMO), Union Pacific (UNP) and others.

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Masimo (MASI) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.

Here's Why You Should Retain Avanos Medical (AVNS) Stock Now

by Zacks Equity Research

Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.

Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

by Zacks Equity Research

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.

Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.

Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.

Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat

by Zacks Equity Research

Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.

BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test

by Zacks Equity Research

BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.

The Zacks Analyst Blog Highlights: Goldman Sachs, Applied Materials, Charles Schwab, Caterpillar and Abbott Lab

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Goldman Sachs, Applied Materials, Charles Schwab, Caterpillar and Abbott Lab

Here's Why You Should Retain DaVita (DVA) in Your Portfolio Now

by Zacks Equity Research

Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.

Zacks.com featured highlights include: Sanderson Farms, Abbott Lab, Caterpillar, CNA Financial and Acushnet Holdings

by Zacks Equity Research

Zacks.com featured highlights include: Sanderson Farms, Abbott Lab, Caterpillar, CNA Financial and Acushnet Holdings

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.

Nalak Das headshot

CEO Confidence of U.S. Corporates Hits 17-Year High: 5 Picks

by Nalak Das

It will be prudent to invest in stocks of U.S. corporate giants as these companies have robust business model and a powerful brand value. These are: GS, AMAT, SCHW, CAT and ABT.

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $123.04 in the latest trading session, marking a -1.89% move from the prior day.

Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.

Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up

by Zacks Equity Research

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

The Zacks Analyst Blog Highlights: Abbott Lab, SAP SE, Freeport-McMoRan, Kraft Heinz and American International Group

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Lab, SAP SE, Freeport-McMoRan, Kraft Heinz and American International Group